© 1984 British Society for Rheumatology
research-article |
CAUSE OF DEATH IN RHEUMATOID ARTHRITIS
1Rheumatism Research Wing, The Medical School Birmingham B15 2TJ
2Cancer Epidemiology Research Unit. University of Birmingham Birmingham B15 2TJ
Correspondence to:
Address correspondence to Dr. D. P. M. Symmons.
A series of 489 consecutive patients with definite or classical rheumatoid arthritis was followed for a mean of 11.2 years. Cohort-analysis of the series showed a three-fold increase in mortality overall in comparison with age- and sex-specific rates in the general population. In patients first seen in hospital early in the course of the disease (<5 years from onset), the excess of deaths from circulatory, respiratory and musculoskeletal disorders was highly significant. Malignant disease and digestive system disorders accounted for a small excess of borderline significance. Patients who were referred later (>5 years from onset) experienced, in addition, a highly significant excess of deaths from infections and disorders of the digestive and genito-urinary system but not from malignant neoplasms.
KEY WORDS: Rheumatoid arthritis, Mortality
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Walker, A. Adebajo, P. Heslop, J. Hill, J. Firth, P. Bishop, and P. S. Helliwell Patient education in rheumatoid arthritis: the effectiveness of the ARC booklet and the mind map Rheumatology, September 1, 2007; (2007) kem171v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bernatsky, M. Hudson, and S. Suissa Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis Rheumatology, July 1, 2007; 46(7): 1157 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M Farragher, M. Lunt, D. K Bunn, A. J Silman, and D. P M Symmons Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register Ann Rheum Dis, April 1, 2007; 66(4): 486 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Klareskog, M Gaubitz, V Rodriguez-Valverde, M Malaise, M Dougados, J Wajdula, and for The Etanercept Study 301 Investigators A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs Ann Rheum Dis, December 1, 2006; 65(12): 1578 - 1584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. C. Hall and N. Dalbeth Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology, December 1, 2005; 44(12): 1473 - 1482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Hakoda, H Oiwa, F Kasagi, N Masunari, M Yamada, G Suzuki, and S Fujiwara Mortality of rheumatoid arthritis in Japan: a longitudinal cohort study Ann Rheum Dis, October 1, 2005; 64(10): 1451 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Escalante, R. W. Haas, and I. del Rincon Paradoxical Effect of Body Mass Index on Survival in Rheumatoid Arthritis: Role of Comorbidity and Systemic Inflammation Arch Intern Med, July 25, 2005; 165(14): 1624 - 1629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K L Hyrich, A J Silman, K D Watson, and D P M Symmons Anti-tumour necrosis factor {alpha} therapy in rheumatoid arthritis: an update on safety Ann Rheum Dis, December 1, 2004; 63(12): 1538 - 1543. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Daneshtalab, R. Z. Lewanczuk, A. Russell, and F. Jamali Rheumatoid Arthritis Does Not Reduce the Pharmacodynamic Response to Valsartan J. Clin. Pharmacol., March 1, 2004; 44(3): 245 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J U Kim, H K Chang, S S Lee, J W Kim, K T Kim, S W Lee, and W T Chung Endothelial nitric oxide synthase gene polymorphisms in Behcet's disease and rheumatic diseases with vasculitis Ann Rheum Dis, November 1, 2003; 62(11): 1083 - 1087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Kitas and N. Erb Tackling ischaemic heart disease in rheumatoid arthritis Rheumatology, May 1, 2003; 42(5): 607 - 613. [Full Text] [PDF]
|
|
|
|
|
|
R. Moots, A. Taggart, and D. Walker Biologic therapy in clinical practice: enthusiasm must be tempered by caution Rheumatology, May 1, 2003; 42(5): 614 - 616. [Full Text] [PDF]
|
|
|
|
|
|
S. Kroesen, A. F. Widmer, A. Tyndall, and P. Hasler Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-{alpha} therapy Rheumatology, May 1, 2003; 42(5): 617 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A D Filer, J M Gardner-Medwin, J Thambyrajah, K Raza, D M Carruthers, R J Stevens, L Liu, S E Lowe, J N Townend, and P A Bacon Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa Ann Rheum Dis, February 1, 2003; 62(2): 162 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Peltomaa, L Paimela, H Kautiainen, and M Leirisalo-Repo Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis Ann Rheum Dis, October 1, 2002; 61(10): 889 - 894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-M. Gordon, R. Hampson, H. A. Capell, and R. Madhok Illiteracy in rheumatoid arthritis patients as determined by the Rapid Estimate of Adult Literacy in Medicine (REALM) score Rheumatology, July 1, 2002; 41(7): 750 - 754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M-M Gordon, E A Thomson, R Madhok, and H A Capell Can intervention modify adverse lifestyle variables in a rheumatoid population? Results of a pilot study Ann Rheum Dis, January 1, 2002; 61(1): 66 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. McEntegart, H. A. Capell, D. Creran, A. Rumley, M. Woodward, and G. D. O. Lowe Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis Rheumatology, June 1, 2001; 40(6): 640 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Raza, J. Thambyrajah, J. N. Townend, A. R. Exley, C. Hortas, A. Filer, D. M. Carruthers, and P. A. Bacon Suppression of Inflammation in Primary Systemic Vasculitis Restores Vascular Endothelial Function: Lessons for Atherosclerotic Disease? Circulation, September 26, 2000; 102(13): 1470 - 1472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N Maiden, H A Capell, R Madhok, R Hampson, and E A Thomson Does social disadvantage contribute to the excess mortality in rheumatoid arthritis patients? Ann Rheum Dis, September 1, 1999; 58(9): 525 - 529. [Abstract] [Full Text]
|
|
|
|
|
|
E. Lindqvist and K. Eberhardt Mortality in rheumatoid arthritis patients with disease onset in the 1980s Ann Rheum Dis, January 1, 1999; 58(1): 11 - 14. [Abstract] [Full Text]
|
|
|
|
|
|
R Munro, E Morrison, A G McDonald, J A Hunter, R Madhok, and H A Capell Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis Ann Rheum Dis, June 1, 1997; 56(6): 374 - 377. [Abstract] [Full Text]
|
|